Atopic dermatitis phenotypes and the need for personalized medicine
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Purpose of review: To describe recent developments in therapies which target the molecular mechanisms in atopic dermatitis. Recent findings: Current advances in the understanding of the molecular basis of atopic dermatitis are leading to the stratification of different atopic dermatitis phenotypes. New therapies offer the option to target-specific molecules involved in the pathophysiology of atopic dermatitis. Current new therapies under investigation aim to modulate specific inflammatory pathways associated with distinctive atopic dermatitis phenotypes, which would potentially translate into the development of personalized, targeted-specific treatments of atopic dermatitis. Summary: Despite the unmet need for well tolerated, effective, and personalized treatment of atopic dermatitis, the current standard treatments of atopic dermatitis do not focus on the individual pathogenesis of the disease. The development of targeted, phenotype-specific therapies has the potential to open a new promising era of individualized treatment of atopic dermatitis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
Simpson, E. L., Bieber, T., Guttman-Yassky, E., Beck, L. A., Blauvelt, A., Cork, M. J., Silverberg, J. I., Deleuran, M., Kataoka, Y., Lacour, J.-P., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1610020 · Cited by 2,110
Weidinger, S., & Novak, N. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00149-x · Cited by 1,908
Self-citationEmollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention
Simpson, E. L., Chalmers, J. R., Hanifin, J. M., Thomas, K. S., Cork, M. J., McLean, W. H. I., Brown, S. J., Chen, Z., Chen, Y., & Williams, H. C. (2014) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2014.08.005 · Cited by 722
Anti–Interleukin-31 Receptor A Antibody for Atopic Dermatitis
Ruzicka, T., Hanifin, J. M., Furue, M., Pulka, G., Mlynarczyk, I., Wollenberg, A., Galus, R., Etoh, T., Mihara, R., Yoshida, H., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1606490 · Cited by 592
Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin
Esaki, H., Brunner, P. M., Renert-Yuval, Y., Czarnowicki, T., Huynh, T., Tran, G., Lyon, S., Rodriguez, G., Immaneni, S., Johnson, D. B., et al. (2016) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2016.07.013 · Cited by 428
Oldhoff, J. M., Darsow, U., Werfel, T., Katzer, K., Wulf, A., Laifaoui, J., Hijnen, D. J., Plötz, S., Knol, E. F., Kapp, A., et al. (2005) · Allergy · doi:10.1111/j.1398-9995.2005.00791.x · Cited by 339
Omalizumab for atopic dermatitis: case series and a systematic review of the literature
Holm, J. G., Agner, T., Sand, C., & Thomsen, S. F. (2017) · International Journal of Dermatology · doi:10.1111/ijd.13353 · Cited by 71
Cited by
Molecular Mechanisms of Atopic Dermatitis Pathogenesis
Sroka-Tomaszewska, J., & Trzeciak, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22084130 · Cited by 577
A Review of the Anti-Inflammatory Effects of Rosmarinic Acid on Inflammatory Diseases
Luo, C., Zou, L., Sun, H., Peng, J., Gao, C., Bao, L., Ji, R., Jin, Y., & Sun, S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00153 · Cited by 336
Update on the Pathogenesis and Therapy of Atopic Dermatitis
Li, H., Zhang, Z., Zhang, H., Guo, Y., & Yao, Z. (2021) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-021-08880-3 · Cited by 277
“The individual pathogenesis urged the development of targeted and phenotype-specific therapies for AD [57].”
BackgroundCutaneous barrier dysfunction in allergic diseases
Leung, D. Y. M., Berdyshev, E., & Goleva, E. (2020) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2020.02.021 · Cited by 190
Welsh, S. E., Xiao, C., Kaden, A. R., Brzezynski, J. L., Mohrman, M. A., Wang, J., Smieszek, S. P., Przychodzen, B., Ständer, S., Polymeropoulos, C., et al. (2021) · Journal of the European Academy of Dermatology and Venereology · doi:10.1111/jdv.17090 · Cited by 44
Metadata
- Authors
- Cabanillas, B., Brehler, A.-C., & Novak, N.
- Venue
- Current Opinion in Allergy & Clinical Immunology
- Published
- 2017-08
- Volume
- 17
- Issue
- 4
- Pages
- 309-315
- ISSN
- 1473-6322 (ISSN-L)
- 1528-4050
- OpenAlex
- W2620852772
- Cited by
- 155
- References
- 7
- FWCI
- 9.00
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Atopic dermatitis phenotypes and the need for personalized medicine. https://app.cochat.ai/papers/10.1097/aci.0000000000000376
- The paper
- Cabanillas, B., Brehler, A.-C., & Novak, N. (2017). Atopic dermatitis phenotypes and the need for personalized medicine. Current Opinion in Allergy & Clinical Immunology. https://doi.org/10.1097/aci.0000000000000376
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.